[111In]In-APH070

Also written as [111In]In-APH070

Radionuclide: In-111
Modality: —
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Neuroendocrine neoplasms Peptide receptor radionuclide therapy

What it is

Compound class: DOTA-conjugated minigastrin peptide analogue (CCK-2 receptor binding peptide)
Target / mechanism: CCK-2 receptor (cholecystokinin subtype 2 receptor / gastrin receptor) PMID 19910426
Clinical application: CCK-2 receptor-expressing tumors, including neuroendocrine tumors PMID 19910426
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC	—	>95%	APH070…APH070 (DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)	21461732 2011 Eur J Nucl Med Mol Imaging DOTA-conjugated peptides were radiolabelled with 111In by incubation with 111InCl3

Need this precursor?We can point you to suppliers for [111In]In-APH070, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 2 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 19910426, 30587465. Compound class inferred from precursor name (not stated outright) -- PMID 19910426: 'DOTA-GSC(succinimidopropionyl-EAYGWNleDF-NH(2))-EAYGWNleDF-NH(2) (MGD5) was selected. The in vitro stability, receptor binding, and internalization of (111)In-MGD5 were studied and compared with those of monomer compound (111)In-APH070.'. Stage set/updated at stage 39 from PMID 19910426: 'In vivo biodistribution and imaging using a SPECT/CT camera were also performed.'.